Abstract: OBJECTIVE To observe the clinical efficacy and safety of division of ziprasidone combined with low dose of haloperidol in the treatment of mental disease refractory auditory hallucinations, and to explore its mechanism. METHODS In line with the inclusion criteria, 60 cases were randomly divided into observation group and control group, 30 cases in each group, control group were treated with single antipsychotic ziprasidone, and the observed group were treated with ziprasidone combined with low dose of haloperidol. Before treatment and after 2, 4, 8 and 12 weeks, positive and negative symptom table(PANSS), the reduction rate of auditory hallucinations scale(AHRS) before and after treatment were used to evaluate the efficacy, and treatment emergent symptom scale(TESS) were used to assess the efficacy and adverse reaction, with a treatment course of 12 weeks. RESULTS Before intervention, there were no significant difference in PANSS score and AHRS score between the observation group and the control group. After intervention there were no significant difference between the two groups in PANSS except positive symptom table, while there was significant difference between the two groups in AHRS. CONCLUSION Ziprasidone combined with low dose of haloperidol in the treatment of mental division disease refractory auditory hallucination effect fully displayed, help with minor side effects, compliance of treatment, disease refractory auditory hallucination of one way as the spirit of the clinical treatment of split.